Skip to main content
main-content

Cardiology

Cardiology

04-12-2020 | Diabetes | News | Article

EMPA-REG OUTCOME: Empagliflozin reduces total CV burden in type 2 diabetes

Empagliflozin reduces the total burden of cardiovascular complications and all-cause hospitalization in people with type 2 diabetes and atherosclerosis, show data from the EMPA-REG OUTCOME trial.

27-11-2020 | Diabetes | News | Article

Healthy lifestyle mitigates elevated heart disease risk in people with type 2 diabetes

People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.

26-11-2020 | Diabetes | News | Article

Type 2 diabetes linked to increased CVD risk even without CV risk factors

The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.

25-11-2020 | Diabetes | News | Article

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

25-11-2020 | Diabetes | News | Article

More than half of people with type 2 diabetes at very high CV risk

A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”

24-11-2020 | Diabetes | News | Article

Age has no impact on CV outcomes with linagliptin vs glimepiride

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

19-11-2020 | Diabetes | News | Article

Targeting fat mass, central adiposity may reduce HF risk in type 2 diabetes

The risk for heart failure falls significantly with reductions in fat mass and waist circumference in overweight or obese people with type 2 diabetes, shows an analysis of data from the Look AHEAD trial.

18-11-2020 | Diabetes | News | Article

Empagliflozin shows heart failure benefits regardless of HbA1c

Empagliflozin reduces the risk for adverse cardiovascular outcomes in people with heart failure and a reduced ejection fraction irrespective of their baseline glycated hemoglobin level, EMPEROR-Reduced trial data show.

17-11-2020 | Diabetes | News | Article

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

17-11-2020 | Diabetes | News | Article

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

28-09-2020 | Diabetes | News | Article

Cardioprotective measures neglected in young-onset type 2 diabetes

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

14-09-2020 | Rheumatology | News | Article

Cardiovascular damage apparent in early RA

Individuals with treatment-naïve early rheumatoid arthritis show evidence of cardiovascular disease that improves following initiation of DMARD therapy, UK research shows.

08-09-2020 | Diabetes | News | Article

Meta-analysis supports mortality reduction with SGLT2 inhibition in HF

A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.

02-09-2020 | Diabetes | News | Article

Age, cardiovascular disease impact amputation risk with canagliflozin

Older patients and those with cardiovascular disease are most likely to have an increased risk for lower limb amputation when newly prescribed canagliflozin, relative to a GLP-1 receptor agonist, research shows.

02-09-2020 | Rheumatology | News | Article

Abatacept, TNF inhibitors linked to reduced CVD risk in RA

A real-world comparison of biologic, targeted synthetic, and conventional DMARDs indicates that TNF inhibitors and abatacept are associated with a reduction in CVD risk in patients with rheumatoid arthritis.

01-09-2020 | Diabetes | News | Article

EMPEROR-Reduced boosts case for SGLT2 inhibition in HF irrespective of diabetes

The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.

21-08-2020 | Diabetes | News | Article

Fasting glucose variability in young adulthood linked to CAC progression in middle age

A prospective study has revealed that greater fasting glucose variability during young adulthood is independently associated with increased risk for coronary artery calcification progression in middle age.

14-08-2020 | Diabetes | News | Article

Dapagliflozin not linked to adverse limb events in DECLARE-TIMI 58

Dapagliflozin reduces the risk for cardiovascular events in people with type 2 diabetes, including those with peripheral artery disease, without increasing the risk for adverse limb events, show DECLARE-TIMI 58 data.

17-07-2020 | Diabetes | News | Article

Updated meta-analysis confirms prediabetes link with mortality, CVD risk

Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.

16-06-2020 | Diabetes | News | Article

VERTIS-CV: Similar MACE risk with ertugliflozin vs placebo in type 2 diabetes

Patients with type 2 diabetes and established atherosclerotic disease who are treated with the SGLT2 inhibitor ertugliflozin have a similar risk for major adverse cardiovascular events to those given placebo, shows the VERTIS-CV trial.